Edition:
United Kingdom

Supernus Pharmaceuticals Inc (SUPN.OQ)

SUPN.OQ on NASDAQ Stock Exchange Global Market

37.62USD
8:59pm GMT
Change (% chg)

$-0.43 (-1.13%)
Prev Close
$38.05
Open
$37.97
Day's High
$38.11
Day's Low
$36.90
Volume
235,750
Avg. Vol
211,334
52-wk High
$61.25
52-wk Low
$30.16

Chart for

About

Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy. In... (more)

Overall

Beta: 1.30
Market Cap(Mil.): $2,149.64
Shares Outstanding(Mil.): 50.70
Dividend: --
Yield (%): --

Financials

  SUPN.OQ Industry Sector
P/E (TTM): 21.31 30.49 33.71
EPS (TTM): 1.99 -- --
ROI: 50.40 14.98 14.48
ROE: 61.13 16.30 15.99

Supernus Pharma's ADHD drug meets main goal in study on adolescents

Supernus Pharmaceuticals Inc said on Thursday its drug for attention deficit hyperactivity disorder met the main goal in a late-stage trial on adolescents, weeks after results from trials testing the drug on children failed to impress investors.

20 Dec 2018

UPDATE 2-Supernus Pharma's ADHD drug meets main goal in study on adolescents

Dec 20 Supernus Pharmaceuticals Inc said on Thursday its drug for attention deficit hyperactivity disorder met the main goal in a late-stage trial on adolescents, weeks after results from trials testing the drug on children failed to impress investors.

20 Dec 2018

Supernus Pharma's ADHD drug meets main goal in late-stage trial

Dec 20 Supernus Pharmaceuticals Inc said on Thursday its drug for attention deficit hyperactivity disorder met the main goal in a late-stage study testing in adolescents.

20 Dec 2018

Supernus Pharma's ADHD treatment fails to impress; shares fall

Supernus Pharmaceuticals Inc's treatment for attention deficit hyperactivity disorder met the main goal of two trials, but shares fell about 16 percent on Thursday as the data failed to convince some investors that the drug was better than rivals.

06 Dec 2018

UPDATE 3-Supernus Pharma's ADHD treatment fails to impress; shares fall

Dec 6 Supernus Pharmaceuticals Inc's treatment for attention deficit hyperactivity disorder met the main goal of two trials, but shares fell about 16 percent on Thursday as the data failed to convince some investors that the drug was better than rivals.

06 Dec 2018

Supernus Pharma's ADHD treatment succeeds in two late-stage studies

Dec 6 Supernus Pharmaceuticals Inc on Thursday said its experimental treatment for attention deficit hyperactivity disorder (ADHD) met the main goal of reducing disorder symptoms in children in two late-stage studies.

06 Dec 2018

Earnings vs. Estimates